CDC recommends new RSV vaccine for infants under 8 months


The Centers for Disease Control and Prevention have recommended infants under eight months old get vaccinated for respiratory syncytial virus (RSV) starting in the fall. The disease is currently the "leading cause of hospitalization among infants in the U.S." Yearly, 58,000 to 80,000 children under 5 years of age, most of whom are infants, are hospitalized because of RSV. Some 100 to 300 children die from the disease every year.
The new vaccine, called nirsevimab, was approved in July. It is an antibody vaccine, which varies from typical vaccines. Regular vaccines "train the body's own immune defenses against the virus," while an antibody vaccine "works to directly fend off the virus in the body," CBS News reported. "This new RSV immunization provides parents with a powerful tool to protect their children against the threat of RSV," said CDC director Mandy Cohen. "RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available."
Almost all children will contract RSV by their second birthday, and the risk spikes every year in the winter and early spring months. The virus causes flu-like symptoms including fever, cough and runny nose. In children under three, "the illness may move into the lungs and cause coughing and wheezing," and in some cases "the infection turns to a severe respiratory disease," according to Cedars-Sinai. "I think that we will look back on this, in a short period of time, and see what a major impact this vote has had on the health and wellbeing of children," Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, said in a meeting for the CDC's Advisory Committee on Immunization Practices, which endorsed giving the vaccine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
The Week contest: Tornado wedding
Puzzles and Quizzes
-
Real estate: A turning point for home prices?
Feature After soaring prices and bidding wars, homebuyers finally have the upper hand
-
Marfa, Texas: Big skies, fine art, and great eating
Feature A cozy neighborhood spot, a James Beard semifinalists, and more
-
Climate change can impact our gut health
Under the radar The gastrointestinal system is being gutted
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
Children's breakfast cereals are getting more unhealthy
Under the radar Your kids may be starting their day with more than a spoonful of sugar
-
The marvelous powers of mucus
The Explainer It's snot just a pesky cold symptom
-
'Wonder drug': the potential health benefits of creatine
The Explainer Popular fitness supplement shows promise in easing symptoms of everything from depression to menopause and could even help prevent Alzheimer's
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
A tick-borne illness is making its rounds in new parts of America
Under the radar Babesiosis, spread through blacklegged or deer tick bites, is a growing risk